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Objectives: to determine the role of polyclonaI antz-baszc Fzbroblast Growth Factor (bFGF) antzbody m mhzbztmg the 
prohferatlon of smooth muscle cells after experlmentaI polytetrafluorethilene (PTFE) arterzal grafting 
Materials: ~n 14 male inbred Lewzs rats (wezght 250 rag) a 1 cm long segment of PTFE was interposed at the level of 
abdominal aorta. Ammals were randomised to recezve polyclonal antz-bFGF antzbody (group A: n=seven ammals) or 
aspec~c zmmunoglobuhn (group B n=seven ammals) Antz-bFGF antibody or aspec~c unmunoglubhn were gwen 
mtraper#oneally at the end of operation, and for the ~rst 2 postoperatwe days Ammals were sacr~ced 7 days after 
surgery, 24 h after mtraperltoneaI m]ectwn of BromodeoxyUr~dm (BrdU) to label prohferatmg smooth muscle cells 
Results: one ammal zn each group died m the imme&ate postoperative permd due to anaesthettc problems All grafts 
were patent at the ttme of sacr~ce. BrdU labelling index was stat~stzcally hzgher in the control group B ammals at the 
level of the anastomotw regwns (proximal anastomosis group B 7 9% vs. group A 4.1%. Distal anastomosis group B 
5 I% vs. group A 2 6% p=O.O09) and at the level of PTFE graft (group B 3 8% vs. group A 2 6% p=0 002), whde 
there was no stastltlcaI &fference between the control thoracic aorta of the two groups. 
Main conclusions: bFGF plays a major role in the proliferatwn of smooth muscle cells at the level of the anastomoses 
after arterial PTFE grafting. Agents able to block the action of bFGF may be useful in lnhzbzt~ng the formation of 
myomtm~al hyperplas~a. 
Introduction Growth factors, cytokines and other chemicals reduce 
and regulate numerous cell functions during the pro- 
Polytetrafluorethylene (PTFE) arterial bypass grafting cess of MH and atherogenesis, '9 particularly, growth 
has become a common procedure in arterial re- factors may modulate cellular proliferation and many 
constructive surgery. Late results, however, are less of them have chemotactic properties. Basic Fibroblast 
than satisfactory because of the high incidence of Growth Factor (bFGF), which is released after endo- 
occlusion. At least one-third of PTFE arterial grafts thelial cell trauma or vascular injury, has been im- 
develop stenoses within 18 months of surgery, and phcated as a major local mitogen active in the MH 
the most common cause of late failure is myointimal process: it is a member of the heparin-bindmg mi- 
hyperplasia (MH) localised at the anastomotlc sites. ~'2 togens, characterlsed by their affinity for heparin and 
MH formation is characterised by an abnormal pro- ability to stimulate both endothelial and smooth 
liferation of smooth muscle cells; factors involved in muscle cell (SMC) proliferation. 1~13 The predominant 
the genesis of MH include local anastomotic factors role of bFGF in the growth of SMC has already been 
such as trauma, compliance mismatch between graft shown experimentally) 4 In previous studies, we 
and artery and abnormal f ow haemodynamics. 3~ Bio- showed experimentally how PTFE grafts, once inserted 
logic events occurring during transit of blood through in the arterial system, release ahigh quantity of growth 
the synthetic graft may contribute to the formation of factors; the production of growth factors from PTFE 
anastomotic MH and accelerated atherosclerosis is arterial grafts was greater than that from veto arterial 
often seen in the arterial tree below a synthetic graft7 grafts and the most significant difference concerned 
bFGF production, is The purpose of our study was to 
Please address all correspondence to. A V Sterpettl, I Cl~uca determine the role of bFGF m MH formation after 
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Material and Methods Briefly, plastic wells (96 wells; Falcon Plastics, Oxnard 
Ca, U S.A.) were coated with hr bFGF (Boehringer 
Experzmental deszgn Mannheim) (10 ng/well), hr acidic fibroblast growth 
factor (10ng/well), platelet derived growth factor 
Male inbred Lewis rats (average weight 250 g) were (10ng/well), transforming rowth factor ~ (20 rig/ 
used for the study. In 14 ammals, a I cm long segment well) and DMEM 0.1% FCS for 8 h at 4 °C. Plates were 
of non-reinforced PTFE (30 mm fibril length, 2 mm then washed twice with PBS and saturated with PBS- 
internal diameter, and 0.39 mm thick; W.L. Gore & gelatin 0.2% for 2 h at 37 °C. Washed wells were then 
Associates Inc, Flagstaff, Arizona) was inserted in the filled with 50 ~tl per well of polyclonal anti-bFGF anti- 
arterial system, at the level of the abdominal aorta, body (0.5 mg). After 2 h of incubation at 37 °C the 
Animals were randomised into two groups: group A wells were washed with PBS-gelatin 0.2%. Peroxidase 
(seven animals) received polyclonal anti-bFGF anti- labeled goat anti-mouse immunoglobuhn antibody 
body, group B (seven animals) received aspecific (Sigma) was added. After 60 min of incubation at 37 °C 
lmmunoglobuhns. Anti-bFGF antibody or aspecific the plates were washed three times in PBS-gelatin 
immunoglobulins were given intraperitoneally at the 0.2% and once m distilled water. O-phenylenediamine 
end of the operation and for the first 2 operative days dihydrochlor~de (0.4 mg/ml) (Sigma) was added as 
to a total of 1.5 mg of 7-globulins. Seven days after substrate for the enzyme Bound specific antibody was 
surgery, the animals were sacrificed, 24 h after intra- quantitatively measured by optical density reading at 
peritoneal injection of BromodeoxyUridin (BrdU) to 492 nm with a spectrophotorneter (Beckman In- 
label proliferating SMC. The PTEE graft, a i cm long struments, Inc, Palo Alto, Ca, U.S.A.). 
segment of aorta above and below the graft and of 
thoracic aorta, were explanted from each animal and 
analysed for labelling index determination. Reductzon ofmitogemc activzty by ant~-bFGF antibody 
Animal care complied with the principles of laborat- 
ory animal care as formulated by the National Society Subconfluent bFGF receptor-bearing Swiss 3T3 cells 
for Medical Research and the Guide for the Care and were used to assay the DNA synthesis timulation 
Use of Laboratory Animals (U.S. Department ofHealth activity of the hr bFGF. The cells were plated m 96 
and Human Science, National Institutes of Health wells plates (Falcon Plastics) at a density of 4 x 10  4 
publication No. 80.23, revised 1985). cells/ml m 200 ~tl of DMEM supplemented with 0 1% 
foetal calf serum. Hr bFGF (10ng/ml) (Boehringer 
Polyclonal antibody to bFGF Mannheim) plus polyclonal antl-bFGF (0.5 rag) were 
added. Negative control received serum free DMEM 
Four BALC/c mice were inoculated intraperitoneally plus anti-bFGF antibody. Tritlated thymidine (0.5 ~tCi 
with human recombinant bFGF (hr bFGF) (Boehringer per well plate) was added, the cultures were zncubated 
for 48 h and collected on Skatron Filters (Skatron In- 
Mannhelm GmbH, Germany) (10 pg/0.25ml per struments Inc, Sterhng, Va, U.S.A.) for ra&oactlvity 
mouse) plus 2.0 x 10 l° Bordetella Pertussis cells and determination i a LKB (LKB Instruments Inc, Gai- 
boosted at weekly intervals for 3 months with 5 ~tg thersburg, Md, U.S.A.) scintillation counter. 
hr bFGF/0 25 ml incomplete Freund's adjuvant per 
mouse. Three days after the last inoculation the im- 
mune serum was obtained. Non-immune serum was 
obtained from non-immunised mice. The protein con- Operative procedures 
centration was determined spectrophotometrically t 
A595 with the Bradford reagent (Sigma). Then the 7- The animals were anaesthetised with intramuscular 
globulin fraction was determined by gel electro- xylazme (3mg/kg) and intramuscular ketamine 
phoresis of immune and non-immune serum, in order (50 mg/kg) supplemented by mtraperitoneal ketamine 
to administer equal amounts of 7-globulin among the for maintenance. Surgery was performed with the use 
two groups, of an operating microscopy (Zeiss OPMI-7D; Carl 
Zeiss, Inc, Thomwood, N.Y.). In both groups, through 
a median laparotomy, the mfrarenal portion of the 
Antz-bFGF antzbody speclj~czty abdominal aorta was identified and both proximal and 
distal control was obtained. A 1 cm long segment of 
The anti-bFGF antibody speczficity was determined non-reinforced PTFE graft was inserted as m- 
by Enzyme Linked Immunosorbent Assay (ELISA). terposztion graft with end-to-end anstomosis with 10-0 
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monofilament ylon suture (Ethicon; Somerville, N.J.) 0 3 
In a continuous fashion. Care was taken to avoid 
unnecessary damage to the graft and the arterial tissue. 0 25 - F 
In the antibody treated group, intraperitoneal in- ± 
oculation of 0.5 mg of antI-bFGF specific antibody (in 0 2 - 
a i ml solution) was performed at the end of the 
intervention; inoculation was repeated at 24 h and 48 h 
from operation. In the control group, with the same o 0 15 - 
modalities and timing of administration, aspecific 
immunoglobulins were inoculated. Seven days after 0.1- 
the operation, animals were anaesthetised with the 
standard technique and the abdomen and chest were 0 o5 - :_ 
opened. The graft, the aorta above and below the graft ~ ~ = ~- 
(1 cm extension in both ways) and a i cm long segment 0 - I I -~  
of thoracic aorta were exposed and excised. Euthanasia DMEM bFOF aFGF PDOF TGF-~ 
was performed with an overdose of ketamine and Fig. 1. Enzyme-hnked lmmunosorbent assay (ELISA)to determine 
xylazine, antl-bFGF antibody speoflclty. The polyclonal ntl-bFGF antibody 
recogmses only hr bFGF, does not react with the structurally related 
aFGF, wl~h PDGF and TGFI3 Each column represents he mean 
value ± s D of three xperiments performed m trlphcate DMEM 
negative control, OD optical density reading at 492 nm. 
BrdU labelling index 
In all animals, an intraperitoneal injection of BrdU, at the whole section length, was utilised as the BrdU 
the dosage of 100 mg/kg,  was performed 24 h before labelling index. The BrdU labelling index was assessed 
sacrifice. At sacrifice, the graft, i cm long segments of as the mean percentage of neointimal smooth muscle 
aorta above and below the graft and of thoracic aorta labelled cells [(labelled nuclei/total nuclei) x 100]. 
were excised. Representative portions of each segment 
of aorta (measuring approximately 3 mm) were dis- 
sected carefully. All specimens were fixed in buffered 
10% formaldehyde and embedded in paraffine with Statistical analysis 
the standard technique. Histologic study was carried 
out on haematoxylin-eosin tained slides, 5 mm serial Data were expressed as mean-t-S.D. Differences be- 
sections mounted on APES (Dako, Glostrup, Denmark) tween the two groups were determined by Student's 
coated slides were cut for immunohistochemical ana- t-test. Differences were considered significant at the 
lysis. Each section was deparaffinlsed in xylene and level of p<0.05. 
rehydrated in ethanol; slides were then placed with 
citrate buffer (10mM pH6.0) in a microwave oven 
(750 W) for three heating cycles of 5 min. Sections were 
stained using anti-BrdU antibody (BU 33, Sigma, St. Results 
Louis, MO, U.S.A ) diluted to 1'50. In addition, anti- 
Factor VIII polyclonal antibody (Dako) at a dilution One animal for each group died in the immediate 
of 1:300 to highlight endothelium and anti-muscle postoperative period for anaesthetic problems. The 
actin antibody (HHF-35, Signet Laboratories, Dedham, remaining rafts were all patent at the time of sacrifice. 
MA, U.S.A.) diluted to 1:100 to identify smooth muscle 
cells, were utilised. The avidin-biotin complex (ABC 
kit, Vector Laboratories, Burlingame, CA, U.S.A.) 
method was performed using diaminobenzidine Spec~city of the antz-bFGF antibody 
(Dako) as a chromogen substrate and the tissues were 
counterstained with Weigert elastin stain to localise The polyclonal anti-bFGF antibody obtained from 
the internal elastic lamina. The neointima was defined Balb/c mice immunised with human recombinant 
as the new cellular layer developing beneath the endo- bFGF recognised only bFGF, did not react with the 
thelium on the luminal side of the internal elastic structurally related aFGF, neither with other growth 
lamina. Finally, the total number of neointimal labelled factors as PDGF and TGF~3 (Fig. 1). The antibody cross- 
and unlabelled cells in each high power field along reacted with rat bFGF. 
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14 000 BrdU labelhng index 
=- 12 000 Reduction of mitogenic activity by anti-bFGF antibody 
means that the mitogenic activity is due to that par- 
ticular growth factor. The polyconal anti-bFGF anti- 
10 000 body was used to inh~bit the in vivo prohferative 
response of SMCs induced by all the overmentioned 
8000 factors. The incorporation of BrdU in SMCs' DNA 
was measured to determine the proliferation rate. 
The labelhng index was reduced with a statistical 
6000 significance (p<0.01) in the anti-bFGF group compared 
with the control group. The difference was evident at 
4000 the level of the proximal anastomosis, distal ana- 
-~ stomosis and PTFE graft. There was no statistically 
sigmficative difference at the level of the thoracic aorta, 
2000 utilised as control, in the two groups (Table 1). 
0 
bFGF DMEM Mmroscopm features 
Fig. 2. Addition of polyclonal ant~-bFGF antibody to the medmm 
of 3T3-Sw~ss cultures exposed to hr bFGF (10 ng/ml) decreased On hght mtcroscopy, the haematoxylin and eosin stain 
the tntmted thym~dme uptake by 53%(p<0 01) DMEM columns allowed us to observe the entire wall of vessel speci- 
represent medmm of 3T3-Sw~ss cultures not exposed to hr bFGF, 
m which polydonal ant~-bFGF antibody has been added Each mens. Counterstaming with We~gert elastin stare per- 
column represents the mean value i s  D of three separate ex- mitted us to h~ghlight he internal elastic lamina m 
per~ments performed m tr~phcate (~) W/o ant~-bFGF, ([13) w~th order to define the neomtimal layer. Beneath the endo- 
ant~-bFGF thelial cell monolayer, a cellular neoint~mal layer was 
identified; this new layer was composed mainly by 
spindle-shaped cells with elongated nuclei. These cells 
Reductmn of mztogemc a tivzty by anti-bFGF antibody resulted strongly immunoreactive for smooth muscle 
actin. Endothelial cells showed immunoreactivity for 
Addition of hr bFGF (10 ng/ml)  to the medium of 3T3 factor VIII related antxgen. 
Swtss cultures resulted in a statistically significant 
increase in tritiated thymidine uptake as compared to 
negative control (p<0.001). Ad&tion of polyclonal anti- Discussion 
bEGF antibody to the medmm of 3T3 Swiss cultures, 
exposed to hr bFGF, decreased the tntiated thymidme Anastomot~c myomtimal hyperplasia formatzon is a 
uptake by 53% (p<0.001) (Fig. 2). complex dynamic process, most common m synthetic 
Fig. 3. BrdU labelling at the level of the proximal anastomoms SMC labelhng was s~gmflcantly lower m the ant~-bFGF treated group 
(group A, F~g 3a) than m the control group (group B, F~g 3b) L=lumen Arrows m&cate SMC labelled nucle~ (ABC method) 
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Fig. 4. BrdU labelhng at the level of the d~stal anastomosis: SMC labelling was s~gmhcantly ower m the ant~-bFGF treated group (group 
A, F G 4a) than m the control group (group B, F~g 4b) L=lumen Arrows mdlcate SMC labelled nucle~ (ABC method) 
Fig. 5. BrdU Iabelhng at the level of PTFE graft SMC labelling was slgmficantly lower in the antl-bFGF treated group (group A, Fig 5a) 
than m the control group (group B, Fig 5b) Arrows m&cate SMC labelled nuclei (ABC method) 
v w-  
j ,~% ~ L ~ : 
Fig. 6. BrdU labelling at the level of thoraclc aorta there was no statlstlcally slgnfflcant difference m SMC labelling between the antl- 
bFGF group (group A, Fig 6a) and the control group (group B, Fig. 6b) L=lumen. Arrows indicate SMC labelled nuclei (ABC method) 
Table 1. BrdU labelling index of smooth muscle cells (%). 
Antl-bFGF treated Control 
(group A) (group B) 
Proximal anastomosis 4 1 q- 1 4 7 9 i 2 8 p = 0 009 
PTFE graft 1 6 ± 0 8 3 8 ± 1 1 p = 0 002 
Distal anastomosls 2.6-{-0 8 5 1 +2 0 p=0 009 
Control thoracic aorta 1 3 ± 0 8 1 4 ± 0.8 p = N S 
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grafts at the level of distal anastomosis. 1'2'~6 The bio- vescicles lmmunoreactive to this molecule. 1°-12 The 
genesis and cause of this pathologic entity has been majorro leofbFGFintheSMCprol i ferat ionprocesshas 
fiercely debated. Local anastomotlc factors eem to play been shown in many stud ies ;  9'14'25'26 Lindner and Reldy 
a ma)or ole. Basslouny et al. 5 found anastomotic MH in have shown that prohferation ofSMC was reduced slg- 
two zones, suture line, as a consequence of vascular nificantly (80%) in rats that received anti-bFGF anti- 
healing, and arterial floor, where flow oscillation and bodies beforeballoon catheter in)ury of carotid artery. In 
relatively low shear stress are present. In either situation our previous tudies we found that PTFE grafts release 
the response was associated with altered flow con- growth factors, much more than in arterial vein grafts, 
ditions. Abbott et al. 4 attributed compliance mismatch with the most striking difference being the amount of 
between the graft and the host artery as being cause of bFGF released by synthetic grafts, is 
anastomot lcMH.O jhaeta l .17demonst ra tedgreater f low In this study we found that, after experimental 
disturbances at this level: they found low wall shear PTFE arterial grafting in rats, the administration of 
stress at the level of the toe and heel of the anastomosis polyclonal antibody anti-bFGF reduced significantly 
and high shear stress on the bed. How these different the proliferation of smooth muscle ceils only in sites 
factors may lead to MH is ill-defined. This pathological where the process is more evidently pathological. This 
reaction develops in the deep layer of the intima close underlines the major role of bFGF in smooth muscle 
to the internal elastic lamina and ls characterised by cell proliferation. Many attempts have been made to 
an abnormal proliferation of endothelial and smooth try to prevent MH formation after PTFE grafts, e.g. 
muscle cells. 18 As well as haemodynamic factors, the anti-aggregants, cortisone and other agents, with poor 
interaction between the vessel wall and circulating results. 27'25 The conclusion of our study is that bFGF 
blood constituents may also be important. This patho- plays a prominent role in the genesis of anastomotlc 
logical process could originate from a damaged endo- MH and open new therapeutic horizon. Agents able 
thelium with consequent actxvation of SMC, that to block the action of bFGF may be useful in inhibiting 
the formation of MH after PTFE bypass grafting to assume aprominent role in the reaction to parietal dam- 
age. 19 Initially, SMC of the tumca media start replicating small arteries. 
more rapidly, then migrate through defects in the in- 
ternal elastic layer. Proliferation at intlmal level is as- 
sociated with the formation of connective tissue References  
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